A Tale of Two Pharmas in Basel

While Novartis quietly packs up the last remnants of its urban manufacturing in Basel, its competitor across the Rhine is doubling down. With a 790 million Swiss franc investment in a new high-tech production facility, Roche is deliberately breaking with the prevailing industry playbook that dictates offloading physical production to cheaper regions abroad or suburban industrial estates.

The project, dubbed Building 51, will house a Synthetic Molecules Facility at Roche’s headquarters in Kleinbasel. Scheduled to become operational by 2030, the highly automated, AI-supported complex will replace existing infrastructure and secure roughly 200 jobs over the long haul. Designed as a fully closed, emission-free operation, the plant will manufacture synthetic active ingredients intended for global drug distribution.

This heavy financial commitment stands in stark contrast to the strategy of main competitor Novartis. Earlier this month, Novartis announced the closure of its final production facility in Basel’s Klybeck district by the end of 2027. That shutdown eliminates 130 local jobs, bringing an end to 150 years of chemical manufacturing history on the site to make room for a new residential development. Novartis plans to shift its Swiss commercial production to sites in Schweizerhalle and Stein, while keeping only research and development within Basel proper—a move that drew vocal criticism from the Unia trade union, which pointed out available space on neighboring campuses.

Local officials in Basel are naturally eager to celebrate Roche's announcement. Cantonal Economic Director Kaspar Sutter characterized the investment as a heartening vote of confidence in a relationship that spans 130 years. Yet, corporate leadership framed the decision in decidedly cold, commercial terms. Chief Executive Officer Thomas Schinecker and Site Head Jürg Erismann brushed aside any notion of simple corporate nostalgia. Operating in a high-cost environment like Switzerland is a calculated trade-off: the immediate geographic proximity of research, development, and production yields efficiencies that compensate for elevated local wages. When high-end quality and specialized technical competence are paramount, even expensive Swiss locations can make fiscal sense.

Written by Sandy van Dongen sandy.vandongen@alpineweekly.com